MUMBAI, India, Sept. 26 -- Intellectual Property India has published a patent application (202517081841 A) filed by Merck Sharp & Dohme Llc, Rahway, U.S.A., on Aug. 28, for 'formulations comprising actriia protein variants.'
Inventor(s) include Panchal, Jainik, P.; Xu, Jun; Pierson, Nicholas, A.; Pavon, Jorge, Alex; Song, Jing; Mccoy, Mark, A.; Giles, Morgan, B.; and Raman, Nisha.
The application for the patent was published on Sept. 26, under issue no. 39/2025.
According to the abstract released by the Intellectual Property India: "In certain aspects, the present disclosure provides stable, liquid pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIA) protein or variant thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and/or excipients."
The patent application was internationally filed on Mar. 07, 2024, under International application No.PCT/US2024/018854.
Disclaimer: Curated by HT Syndication.
